GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2008

EPIX Earns $5.5M Milestone from GSK

  • EPIX Pharmaceuticals achieved a key milestone related to the third of three discovery programs under its collaboration with GlaxoSmithKline (GSK), triggering a $5.5 million payment.

    Using its integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates to move forward into lead optimization in its GPCR discovery research.

    EPIX is now entitled to receive a milestone payment of $3 million and an additional $2.5 million for its overall progress in the discovery partnership with GSK. EPIX previously received two milestone payments totaling $6 million for the other two discovery programs.

    “Our in silico approach to drug discovery continues to deliver results and has allowed us to rapidly progress lead candidates into lead-optimization programs,” notes Sheila DeWitt, Ph.D., vp of discovery at EPIX.

    In December 2006, EPIX and GSK announced a worldwide, multitarget strategic collaboration to discover, develop, and market novel medicines targeting four GPCRs for the treatment of a variety of diseases. EPIX received total initial payments of $35 million, including $17.5 million through the purchase of its common stock.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »